UBS initiates coverage of Mineralys Therapeutics with neutral rating and $29 target price
MLYS•UBS initiated coverage of Mineralys Therapeutics with a neutral rating and a $29 target price.
Related News
Amgen target price cut to $378 from $388 by Guggenheim
AMGN•
UBS cuts Alignment Healthcare target price to $9 from $22
ALHC•
Shattuck Labs gets UBS buy rating with $17 target price
STTK•
Lobo Technologies signs exclusive senior-care AI cooperation with Land Crest Advisory
LOBO•
Low-sulphur gasoil deliveries for October fall at expiry
USO•